Ghent, Belgium

Myriam Behgyn

This inventor holds 2 USPTO granted patents. Top assignee: Devgen Nv. Active years: 2003-2006.


% Patents Active = 50.0

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2003-2006

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Myriam Behgyn: Innovator in Pharmacological Screening

Introduction

Myriam Behgyn is a notable inventor based in Ghent, Belgium. She has made significant contributions to the field of pharmacological screening through her innovative methods involving nematode worms. With a total of 2 patents, her work is paving the way for advancements in drug discovery.

Latest Patents

Myriam's latest patents focus on methods of screening compounds for potential pharmacological activity using nematode worms. The inventions specifically relate to the use of modified nematodes that possess certain characteristics advantageous for compound screening. These characteristics include constitutive pharyngeal pumping, increased gut permeability, and altered gut molecular transport. Additionally, her patents provide methods for selecting suitably modified nematodes from a population, enhancing the efficiency of pharmacological assays.

Career Highlights

Myriam Behgyn is currently associated with Devgen NV, where she continues to develop her innovative ideas. Her work has garnered attention in the scientific community, contributing to the understanding of pharmacological activities through novel screening methods.

Collaborations

Some of her notable coworkers include Thierry Bogaert and Richard Feichtinger, who collaborate with her on various projects within the company.

Conclusion

Myriam Behgyn's contributions to pharmacological screening through her innovative use of nematodes highlight her role as a leading inventor in her field. Her patents are instrumental in advancing drug discovery methodologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…